Literature DB >> 28498412

Emmprin, released as a microvesicle in epithelioid sarcoma, interacts with fibroblasts.

Mikiko Aoki1, Kaori Koga1, Makoto Hamasaki1, Nagayasu Egawa2, Kazuki Nabeshima1.   

Abstract

Emmprin (extracellular matrix metalloproteinase inducer, CD147) is a glycosylated transmembrane protein, consisting of two immunoglobulin domains, that stimulates the production of matrix metalloproteinases (MMPs) by tumor-associated fibroblasts. These effects play important roles in tumor invasion and metastasis. However, the precise mechanisms by which emmprin acts on fibroblasts have not been fully elucidated, especially in sarcoma cells. Previously, we demonstrated that emmprin, expressed in conditioned medium collected from the epithelioid sarcoma cell line (FU-EPS-1), stimulates MMP-2 production via interactions with fibroblasts. In this study, we used microvesicles derived from sarcoma cells, and determined whether emmprin exists in the microvesicles, which enhance the production of MMP-2 via fibroblasts. Microvesicles released from FU-EPS-1 cells were shown to contain full-length emmprin, identified as a 45-kDa protein characterized by polylactosamine glycosylation. Microvesicles collected from FU-EPS-1 cells transfected with emmprin-specific siRNA or transduced with shRNA displayed significantly reduced MMP-2 production by fibroblasts compared with those from control-transfected cells. Our findings show that emmprin is released through microvesicle shedding in sarcoma cells, and emmprin in microvesicles regulates MMP-2 production by influencing the activity of fibroblasts located at sites distant from the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28498412     DOI: 10.3892/ijo.2017.3986

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Message in the bottle: regulation of the tumor microenvironment via exosome-driven proteolysis.

Authors:  Agathe Quesnel; Amy Broughton; George S Karagiannis; Panagiota S Filippou
Journal:  Cancer Metastasis Rev       Date:  2022-04-08       Impact factor: 9.264

2.  Interstitial collagenase MMP-1 and EMMPRIN in cell lines and in clinical specimens of cervical squamous cell carcinoma.

Authors:  Nina I Solovyeva; Olga S Timoshenko; Elena V Kugaevskaya; Tatyana A Gureeva
Journal:  Mol Biol Rep       Date:  2021-09-08       Impact factor: 2.316

3.  Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma.

Authors:  Masaru Miyazaki; Mikiko Aoki; Yasuko Okado; Kaori Koga; Makoto Hamasaki; Takashi Nakagawa; Toshifumi Sakata; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2020-06-22       Impact factor: 6.716

Review 4.  Extracellular Vesicles and Matrix Remodeling Enzymes: The Emerging Roles in Extracellular Matrix Remodeling, Progression of Diseases and Tissue Repair.

Authors:  Muhammad Nawaz; Neelam Shah; Bruna Riedo Zanetti; Marco Maugeri; Renata Nacasaki Silvestre; Farah Fatima; Luciano Neder; Hadi Valadi
Journal:  Cells       Date:  2018-10-13       Impact factor: 6.600

5.  Ivabradine-Stimulated Microvesicle Release Induces Cardiac Protection against Acute Myocardial Infarction.

Authors:  Rafael Ramirez-Carracedo; Laura Tesoro; Ignacio Hernandez; Javier Diez-Mata; Laura Botana; Marta Saura; Marcelo Sanmartin; Jose Luis Zamorano; Carlos Zaragoza
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

Review 6.  The Role of Cancer-Associated Fibroblasts and Extracellular Vesicles in Tumorigenesis.

Authors:  Issraa Shoucair; Fernanda Weber Mello; James Jabalee; Saeideh Maleki; Cathie Garnis
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

7.  The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p.

Authors:  Delphine Garnier; Edward Ratcliffe; Joséphine Briand; Pierre-François Cartron; Lisa Oliver; François M Vallette
Journal:  Biomedicines       Date:  2022-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.